Remicade (infliximab) - J&J
Humira (adalimumab) - AbbVie
Tremfya (guselkumab) - J&J
Omvoh (mirikizumab-mrkz) - Eli Lilly
Stelara (ustekinumab) - J&J
Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim
Rinvoq (upadacitinib) - AbbVie
Entyvio (vedolizumab) - Takeda
Differential long-term efficacy of biologic and small-molecule therapies by disease location in moderate-to-severe luminal Crohn's disease: a systematic review and network meta-analysis. (PubMed, Inflamm Bowel Dis) - Oct 10, 2026 - "Relative efficacy of advanced therapies in luminal CD varied by disease location. These findings support consideration of disease location in personalized treatment decision-making to improve clinical outcomes." 
Journal • Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease
http://www.ncbi.nlm.nih.gov/pubmed/42850680
 
Jacob Tveiten Bjerrum; Jakob Benedict Seidelin; Kavini Kalinga Bandara Pkb; Mohamed Attauabi; Sóley Poulsen Dalsgarð
 
Oct 10, 2026
 
Prev Next